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ABSTRACT  
Introduction: Specific diagnosis which provides diagnostic, prognostic, and therapeutic information to guide patient care defines the primary 
goal of sarcoma management and care. The role of immunohistochemistry, using vimentin (mesenchymal linage marker) and cytokeratin 
(epithelial linage marker) as basic markers for diagnosis and classification of sarcomas for specific management strategies and prognosis was 
elucidated in the present study. 
Materials and Methods: Twenty four (24) archived paraffin wax processed tissue block sarcoma samples were randomly selected from the 
histopathology Laboratories and museums of the Nnamdi Azikiwe University Teaching Hospital (NAUTH) Nnewi and National hospital Abuja 
and necessary data obtained from records. Blocks were re-embedded with fresh paraffin wax and 3µ thick sections cut with the aid of a rotary 
microtome. Haematoxylin and Eosin staining method was employed to confirm diagnosis before proceeding to immunohistochemistry. 
Antibodies for vimentin and pancytokeratin were employed for immunohistochemistry while exposed mouse and rabbit specific  horseradish 
peroxides/diaminobenzidine detection IHC kit was employed for immunostaining.  
Results: The mean age of patients was 26 years while the ages range from 11 to 48 years with 14 (58.3%) females and 10 (41.7%) males . 
Vimentin had strong positive immunoreactivity for all sarcoma samples whereas cytokeratin had positive immunoreactions for synovial 
sarcoma only, which also showed co-expression of both genes.  
Conclusion: Vimentin and cytokeratin may play vital role as basic biomarkers not only for diagnosis and characterization of sarcomas but for 
specific management regime and prognostication. However, IHC must be performed at high standard using appropriate antibodies,  samples and 
reagents.  
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1.0 INTRODUCTION  
Vimentin is a gene which encodes for type III intermediate 
filament protein. Intermediate filaments, along with 
microtubules and actin microfilaments constitute the 
cytoskeleton. It has a role in neuritogenesis and cholesterol 
transport and functions as an organizer of a number of other 
critical proteins involved in cell attachment, migration, and 
signaling with its mutations associated with congenital 
cataracts in human patients. Vimentin expressed in certain 
types of carcinomas (renal cell carcinoma, spindle cell 
carcinoma), as well as lymphomas and melanomas It is also 
is expressed in mesenchymal cells though, not specific for 
them 1. Due the crucial role of vimentin in maintaining 
muscle cyto-architecture, it is considered an essential 
marker for muscle regeneration 2. Cytokeratins are members 
of the keratin gene family and consists of basic or neutral 
proteins arranged in pairs of heterotypic keratin chains and 
co-expressed during differentiation of simple and stratified 
epithelial tissues. According to Wei et al 1, they are proteins 
of keratin-containing intermediate filaments found in the 
intracytoplasmic cytoskeleton of epithelial tissue. They are 
specifically expressed in the simple epithelia lining the 
cavities of the internal organs and in the gland ducts and 
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blood vessels and therefore, are basic makers for 
carcinomas. Due to the expression pattern of vimentin and 
cytokeratins in cancers, their immuno-reactivity pattern 
play a vital role in basic characterization of neoplasms into 
carcinomas and sarcomas 2, 3, 4, 5. It is noteworthy however, 
that both genes have their pitfalls as biomarkers of 
characterization of sarcomas and carcinomas. Wei et al 1 in a 
review report on soft tissue immunohistochemistry update 
noted that vimentin may be expressed in certain types of 
carcinomas and may not be expressed in some mesenchymal 
tumours. The authors however, opined that if the 
mesenchymal tissue is negative for vimentin, it may indicate 
that the tissue is not of a mesenchymal differentiation. 
Cytokeratin, similarly may be expressed in some sarcomas 
especially epitheloid sarcomas 2, 4. Vimentin, though, cannot 
solely be used to differentiate mesenchymal from non 
mesenchymal neoplasms, the role as screening marker for 
neoplasms of mesenchymal linage cannot be emphasized 4. 
The authors further noted frequent co-expression of 
vimentin and cytokeratin in some carcinomas which may 
suggest certain types of epithelial tumors as possible 
primary sites in the evaluation of metastatic tumors. 
Sarcomas are connective tissues malignant neoplasms 
usually found in the skeletal muscle, fat, tendons, fibrous 
tissue, smooth muscle and the neurovascular elements that 
support these components and in bone with diverse and 
varied histogenesis6. Though, believed to account for 1% of 
all human malignancies, the growing incidence, the very 
aggressive and invasive nature and the propensity of most 
sarcomas to metastasize has brought it to limelight as a 
major health challenge 6. Sarcomas have predilections for 
children and young adults with a male to female ratio of 2:17, 
8. Dermatofibrosarcoma protuberans, malignant peripheral 
nerve sheath tumour, osteoblastic osteosarcoma, 
fibromyxoma, malignant mesenchymal tumour, 
fibromyxoma, alveolar rhabdomyosarcoma, metastatic 
liposarcoma, synovial sarcoma, low grade leiomyosarcoma 
to mention but a few are examples of most commonly 
diagnosed sarcoma cases in Nigeria 8. The wide 
heterogeneous nature of sarcomas, with greater than 100 
histological types and subtypes with considerable 
morphological overlaps between the different diagnostic 
entities 5 makes it very challenging in establishing definitive 
diagnosis of most sarcoma types. Furthermore, sarcomas 
assume poorly differentiated, undifferentiated with no 
obvious line of differentiation or may even form as 
secondary implant (metastatic tumours) in distant sites, 
thereby increasing the challenge of definitive diagnosis. 
According to Wei et al 1 the general approach to reaching a 
definitive differential diagnosis of soft tissue tumors is to 
first consider clinicoradiologic, histomorphologic, and 
cytomorphologic features of the tumour. Tumours with 
obvious line of differentiation such as smooth-muscle, 
skeletal-muscle, vascular, neural, and Chondro-osseous 
lineages may be diagnosed with morphological features. 
Contrariwise however, immunostaining, using appropriate 
marker will be required to actualize diagnosis.    
In order actualize definitive and specific diagnosis that 
provides diagnostic, prognostic, and therapeutic information 
to guide patient care, immunohistochemistry play a crucial 
role 1. The role of immunohistochemical expressions of 
vimentin and cytokeratin, as afore stated, in the basic 
classification of sarcomas cannot be overemphasized. The 
present study aimed at evaluating the immunohistochemical 
expression pattern of vimentin and cytokeratin using 
selected samples of commonly diagnosed sarcomas in our 
facility. The expression pattern among the implications will 
highlight the role of the genes in basic characterization of 
sarcomas which is a basic a critical step towards patients’ 
care and management especially in a middle income country 
like Nigeria. 
2.0 MATERIALS AND METHOD 
2.1 Study area/ Study design 
This was a cross sectional study using 24 archived samples 
of already diagnosed sarcoma which was carried out at the 
Nnamdi Azikiwe University Teaching Hospital, Nnewi and 
National hospital Abuja. 
2.2 Ethical approval  
Ethical approval to carry out this study was obtained from 
the Ethical Committee of Nnamdi Azikiwe University 
Teaching Hospital (NAUTH) Nnewi.  
2.3 Sample collection 
Twenty four (24) archived paraffin wax processed tissue 
block sarcoma samples were randomly selected from the 
histopathology Laboratories and museums of the Nnamdi 
Azikiwe University Teaching Hospital (NAUTH) Nnewi and 
National hospital Abuja. Necessary data were obtained from 
clinical records, operation notes and histopathology reports 
of the patients.  
2.4 Tissue preparation 
Tissue blocks were re-embedded in fresh paraffin wax, 3µ 
thick sections cut with the aid of a rotary microtome, cut 
sections floated out on a lukewarm Leica water bath, 
mounted on slides previously coated with poly-l-lysine, 
drained, labelled and placed on Leica hot plate in order to 
dry and affix the tissue onto the slides.    
2.5 Staining 
Cut Sections were stained by Haematoxylin and Eosin (H&E) 
method and morphological diagnosis of each sample 
confirmed before proceeding to immunostaining.  
2.6 Immunohistochemical Staining (IHC) 
IHC of test materials and positive controls were carried 
according to a method by Nishio et al 9. Antibodies for 
vimentin and pancytokeratin were employed for 
immunohistochemistry. Exposed Mouse and Rabbit Specific 
horseradish peroxidase/diaminobenzidine (HRP/DAB) 
detection IHC kit was employed for immunostaining while 
detection of immunoreactivity was performed according to 
manufacturer’s instruction.  Both antibodies and detection 
kits were procured from Abcam Plc Cambridge UK.  
2.7 Immunoreactivity Scoring  
Immunoreactivity was semi-quantitatively scored according 
to Zlobec et al 10. This was based on percentage of cells 
(area) that will stain positive and the intensity of the 
staining (strong, moderate, weak). A score of 5+ was 
assigned to 80% or more of epithelial and/ or stromal cells 
that stained positive with strong intensity, 4+ was assigned 
to 50% or more (but less than 80%) of epithelial cells and/ 
stromal cells with strong intensity or 80% of cells or more 
with moderate to weak intensity; 3+ was assigned to 30% or 
more of epithelial and/ or stromal cells with strong intensity 
or 50% or more (but less than 80%) of positive cells with 
moderate to weak intensity;  2+ was assigned to 10% or 
more cells that stained positive with strong intensity or 30% 
or more ( but less than 50%) that stained moderate to weak 
and 1+ was assigned to 10% or more cells ( less than 30% of 
positive cells) that stained positive with moderate to weak 
intensity; 0 was assigned to less than 10% of positivity 
irrespective of the intensity of staining. 
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2.8 Data Analyses 
Numerical data were summarized using mean and standard 
deviation, whereas categorical data were being presented 
using frequency and proportion. Immunoreactivity pattern 
was expressed as percentages.  
3.0 RESULTS  
The mean age of patients was 26 years while the ages range 
from 11 to 48 years with 14 (58.3%) females and 10 
(41.7%) males. The breakdown of sarcoma samples were as 
follows: 4 dermatofibrosarcoma protuberans, 4 malignant 
peripheral nerve sheath tumour, 4 fibromyxoma and 2 each 
of osteoblastic osteosarcoma, malignant mesenchymal 
tumour, alveolar rhabdomyosarcoma, metastatic 
liposarcoma, synovial sarcoma and low grade 
leiomyosarcoma. Histopathological and immunoreactivity 
features for vimentin and cytokeratin were as shown in 
Table 1. Vimentin had strong positive immunoreactivity for 
all sarcoma samples where as cytokeratin had positive 
immunoreactions for synovial sarcoma only, which also 
showed co-expression of both genes Photomicrographs of 
immunohistochemical staining pattern of anti vementin and 
cytokeratin sarcoma samples are as shown in (Figure 1).
 
Table 1: Histopathological and immunoreactivity features for vimentin and cytokeratin 
Tumour type No of samples Vimentin Cytokeratin 
Dermatofibrosarcoma protuberans 4 4(100%) 4+(2), 5+(2) 0(0%) 
Malignant peripheral nerve sheath tumour 4 4(100%) 5+(4) 0(0%) 
Osteoblastic osteosarcoma 2 4(100%) 4+(2) 0(0%) 
Fibromyxoma 4 4(100%) 5+(4) 0(0%) 
Malignant mesenchymal tumour 2 2(100%) 5+(2) 0(0%) 
Alveolar rhabdomyosarcoma 2 2(100%) 5+(2) 0(0%) 
Metastatic liposarcoma 2 2(100%) 5+(2) 0(0%) 
Synovial sarcoma 2 2(100%) 5+(2) 0(0%) 
Low grade leiomyosarcoma 2 2(100%) 5+(2) 2(100%) 3+(2) 
 
 
 
 
Figure 1: Immunohistochemical staining pattern of anti vimentin and cytokeratin 
A: Strongly positive vimentin staining for low synovial sarcoma (X400), B: Strongly positive vimentin staining for low grade 
leiomyosarcoma (X400), C: Strongly positive vimentin staining for fibromyxoma (X400), D: Focally positive cytokeratin staining 
for synovial sarcoma (X400). 
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4.0 DISCUSSION 
The significance role of IHC expression features of vimentin 
and cytokeratin in characterization of sarcoma have been 
reported 1, 3, 4, 5. The present study reported 26 years  as the 
mean age of patients,  while the ages range from 11 to 48 
years with a male to female ratio of 1:1.4, thus agreeing with 
the finding of Ikeri et al 11 who reported a median age of 33 
years and a male to female ratio of 1:1.3 in an earlier study 
on the histological types of soft-tissue sarcomas at the Lagos 
University Teaching Hospital but differs from that of Dauda 
et al 8 and Mandong et al 7 who reported male to female ratio 
of 2:1 in a similar but separate studies. The authors however, 
corroborated the present study on the most commonly 
affected age ranges and the most commonly diagnosed 
sarcomas in Nigeria. The sight deviation from male to female 
ratio though not very significant could be a function of time 
and sample size. 
Strongly positive vimentin immonoreactivity was reported 
for all sarcoma samples and negative cytokeratin expression 
except for synovial sarcoma.  This agrees with earlier studies. 
Bashyal et al 3 reported positive vimentin immunoreactivity 
and negative cytokeratin IHC staining for most round cell 
malignant sarcomas, which led them to conclude that IHC 
provide important tool for clear distinction between 
tumours. This finding not only highlights the need for 
inclusion of IHC as an important ancillary diagnostic tool but 
strongly support the application of vimentin and keratin IHC 
for both diagnosis and characterization of sarcomas. Suffice 
it to note once again that sarcomas with their characteristic 
divergent histogenesis with the attendant morphological 
presentations most times cannot be granted definitive 
diagnosis using only morphological appearance, hence the 
need for IHC. Vimentin and keratin which are known 
markers of mesenchymal and epithelial linage respectively 
present an indispensible tool in characterization of sarcomas 
especially when the linage is not obvious. Despite the fact 
that Wei et al 1 opined that vimentin positivity has a limited 
value in the diagnosis of soft tissue tumors, the authors 
however, accepted its role in establishing that a tumour is of 
mesenchymal differentiation and not of epithelial 
differentiation. The co-expression of vimentin and keratin in 
synoval sarcoma could be explained by the nature of the 
tumour in question. According to Morgan 1, synoval sarcoma 
may either be biphasic (with both mesenchymal and 
epithelial components present) or monophasic (with either 
mesenchymal or epithelial morphology) histologically. 
Histologically biphasic tumour show positive 
immunoreactivity for both vimentin and cytokeratin while 
monophasic type show immunoraectivity for either of the 
genes depending on their linage. This fact further established 
the role of the markers not only for diagnosis and 
characterization but for determination specific 
therapy/management options towards better patients’ care 
and treatment. Besides the application of vimentin and 
cytokeratin IHC in diagnosis and characterization of 
sarcomas it aids their management and prognosis. This was 
the view of Parham 5 in his reported on the imperative of IHC 
and its potential applications, not just for diagnosis and 
prognostication, but for personalized therapy decisions. The 
strong positivity of vimentin in all sarcoma samples studied 
not only agreed with previous studies but validates its 
presence in mesenchymal tumours.  
 
5.0 CONCLUSION 
It could be concluded from the finding of the present study 
that vimentin and cytokeratin may play vital role as basic 
biomarkers not only for diagnosis and characterization of 
sarcomas but for specific management regime and 
prognostication. However, IHC must be performed at high 
standard using appropriate antibodies, samples and 
reagents.  
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